logo
  

Bicycle Therapeutics Says Genentech Expands Collaboration For Immuno-oncology Therapies

Bicycle Therapeutics plc (BCYC) on Tuesday said Genentech, a member of the Roche Group, has expanded its 2020 collaboration agreement for Bicycle's proprietary bicyclic peptide technology (Bicycle)-based immuno-oncology therapies.

As per the terms of the 2020 agreement, Genentech has exercised an option to include a new program under the agreement, triggering a $10 million payment to Bicycle, the company said.

Compounds in Bicycle's wholly owned oncology pipeline, including its immuno-oncology candidates, are not included in the collaboration, Bicycle added.

"We believe the expansion of our collaboration underscores the potential utility of Bicycles compared to other modalities, as well as the potential broad applicability of Bicycles in a wide-range of targets," said Kevin Lee, , Chief Executive Officer of Bicycle Therapeutics.

Bicycle is evaluating BT5528, a second-generation Bicycle Toxin Conjugate (BTC) targeting EphA2, and BT8009, a second-generation BTC targeting Nectin-4, in Phase 1/2 trials.

Further, BT1718, a BTC that targets MT1-MMP, is being investigated in an ongoing Phase 1/2a study sponsored by the Centre for Drug Development of Cancer Research UK.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Home improvement company Lowe's and pet retailer Petco Health and Wellness Co. are set to launch a pilot store-in-store program whereby a total home solution will be offered to customers by bringing home improvement as well as pet care products, services and expertise together under the same roof. Chevron Corporation (CVX) reported fourth quarter profit of $5.1 billion or $2.63 per share, compared to a loss of $665 million or $0.33 per share, previous year. The company's U.S. upstream operations earned $2.97 billion, compared to $101 million, a year ago. The company said the improvement was primarily... While reporting financial results for the fourth quarter on Friday, Colgate-Palmolive Co. (CL) initiated its earnings and sales growth guidance for the full-year 2022. For fiscal 2022, the company now expects earnings per share to grow in double-digit percentage and adjusted earnings per share growth...
Follow RTT